StockNews.com Upgrades IQVIA (NYSE:IQV) to Buy

IQVIA (NYSE:IQV) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Wednesday.

IQV has been the topic of a number of other reports. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Truist Financial reduced their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. UBS Group boosted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Price Performance

IQVIA stock opened at $216.34 on Wednesday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a 50-day moving average price of $236.50 and a 200 day moving average price of $230.16. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The stock has a market cap of $39.44 billion, a P/E ratio of 28.10, a PEG ratio of 2.09 and a beta of 1.49.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of IQVIA

Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc raised its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the second quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 2nd quarter valued at $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.